An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Summary

This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.

Timeline

Start

2014-03

Primary completion

2015-06

Completion

2015-06

Outcome

Outcome not reported

Stopped: “Other - not a safety issue”

Drugs

Indications